
WilmerHale Reps Spark Therapeutics in Licensing Agreement with Selecta Biosciences

DECEMBER 15, 2016

Spark Therapeutics and Selecta Biosciences, Inc. announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta's proprietary Synthetic Vaccine Particles platform technology for co-administration with gene therapy targets, including FVIII for hemophilia A, as well as exclusive options for up to four additional undisclosed genetic targets.

Subject to the terms of the agreement, Spark Therapeutics will make an initial \$10 million cash payment to Selecta and purchase \$5 million of Selecta's common stock. Within 12 months of the agreement's signing, Spark Therapeutics has agreed to pay Selecta an additional \$5 million in cash and to purchase \$10 million of Selecta's common stock. Selecta will be eligible for up to \$430 million in milestone payments for each target, with up to \$65 million being based on Spark Therapeutics' achievement of specified development and regulatory milestones and up to \$365 million for specified commercial milestones.

Partners [Steven Barrett](#) and [Lia Der Marderosian](#), Counsel [Lily Wound](#), and Senior Associates [Ryan Mitteness](#) and [Jenna Ventrino](#) represented Spark Therapeutics in this transaction.

[Read the client's formal press release.](#)